-
Something wrong with this record ?
Preclinical characterisation of gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications
K. Krasulova, B. Neuzilova, K. Dvorakova Bendova, Z. Novy, M. Popper, M. Hajduch, M. Petrik
Status not-indexed Language English Country England, Great Britain
Document type Journal Article
Grant support
LX22NPO5103
Next generation (EU)
Project ENOCH No. CZ.02.1.01/0.0/0.0/16_019/0000868
the European Regional Development Fund
EATRIS-CZ LM2023053
the Czech Ministry of Education, Youth and Sports through project EATRIS
NLK
Directory of Open Access Journals
from 2016
PubMed Central
from 2016
Europe PubMed Central
from 2016
ProQuest Central
from 2016-06-01
Health & Medicine (ProQuest)
from 2016-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2016
Springer Journals Complete - Open Access
from 2017-01-01
Springer Nature OA/Free Journals
from 2017-01-01
- Publication type
- Journal Article MeSH
BACKGROUND: Siderophores are small iron-binding molecules produced by microorganisms to facilitate iron acquisition from the environment. Radiolabelled siderophores offer a promising solution for infection imaging, as they can specifically target the pathophysiological mechanisms of pathogens. Gallium-68 can replace the iron in siderophores, enabling molecular imaging with positron emission tomography (PET). Stereospecific interactions play a crucial role in the recognition of receptors, transporters, and iron utilisation. Furthermore, these interactions have an impact on the host environment, affecting pharmacokinetics and biodistribution. This study examines the influence of siderophore stereoisomerism on imaging properties, with a focus on ferrirubin (FR) and ferrirhodin (FRH), two cis-trans isomeric siderophores of the ferrichrome type. RESULTS: Tested siderophores were labelled with gallium-68 with high radiochemical purity. The resulting complexes differed in their in vitro characteristics. [68Ga]Ga-FRH showed less hydrophilic properties and higher protein binding values than [68Ga]Ga-FR. The stability studies confirmed the high radiochemical stability of both [68Ga]Ga-siderophores in all examined media. Both siderophores were found to be taken up by S. aureus, K. pneumoniae and P. aeruginosa with similar efficacy. The biodistribution tested in normal mice showed rapid renal clearance with low blood pool retention and fast clearance from examined organs for [68Ga]Ga-FR, whereas [68Ga]Ga-FRH showed moderate retention in blood, resulting in slower pharmacokinetics. PET/CT imaging of mice injected with [68Ga]Ga-FR and [68Ga]Ga-FRH confirmed findings from ex vivo biodistribution studies. In a mouse model of S. aureus myositis, both radiolabeled siderophores showed radiotracer accumulation at the site of infection. CONCLUSIONS: The 68Ga-complexes of stereoisomers ferrirubin and ferrirhodin revealed different pharmacokinetic profiles. In vitro uptake was not affected by isomerism. Both compounds had uptake with the same bacterial culture with similar efficacy. PET/CT imaging showed that the [68Ga]Ga-complexes accumulate at the site of S. aureus infection, highlighting the potential of [68Ga]Ga-FR as a promising tool for infection imaging. In contrast, retention of the radioactivity in the blood was observed for [68Ga]Ga-FRH. In conclusion, the stereoisomerism of potential radiotracers should be considered, as even minor structural differences can influence their pharmacokinetics and, consequently, the results of PET imaging.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005659
- 003
- CZ-PrNML
- 005
- 20240412130947.0
- 007
- ta
- 008
- 240405s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s41181-024-00249-z $2 doi
- 035 __
- $a (PubMed)38436776
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Krasulova, Kristyna $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 779 00, Olomouc, Czech Republic. kristyna.krasulova@upol.cz $1 https://orcid.org/0000000283036847
- 245 10
- $a Preclinical characterisation of gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications / $c K. Krasulova, B. Neuzilova, K. Dvorakova Bendova, Z. Novy, M. Popper, M. Hajduch, M. Petrik
- 520 9_
- $a BACKGROUND: Siderophores are small iron-binding molecules produced by microorganisms to facilitate iron acquisition from the environment. Radiolabelled siderophores offer a promising solution for infection imaging, as they can specifically target the pathophysiological mechanisms of pathogens. Gallium-68 can replace the iron in siderophores, enabling molecular imaging with positron emission tomography (PET). Stereospecific interactions play a crucial role in the recognition of receptors, transporters, and iron utilisation. Furthermore, these interactions have an impact on the host environment, affecting pharmacokinetics and biodistribution. This study examines the influence of siderophore stereoisomerism on imaging properties, with a focus on ferrirubin (FR) and ferrirhodin (FRH), two cis-trans isomeric siderophores of the ferrichrome type. RESULTS: Tested siderophores were labelled with gallium-68 with high radiochemical purity. The resulting complexes differed in their in vitro characteristics. [68Ga]Ga-FRH showed less hydrophilic properties and higher protein binding values than [68Ga]Ga-FR. The stability studies confirmed the high radiochemical stability of both [68Ga]Ga-siderophores in all examined media. Both siderophores were found to be taken up by S. aureus, K. pneumoniae and P. aeruginosa with similar efficacy. The biodistribution tested in normal mice showed rapid renal clearance with low blood pool retention and fast clearance from examined organs for [68Ga]Ga-FR, whereas [68Ga]Ga-FRH showed moderate retention in blood, resulting in slower pharmacokinetics. PET/CT imaging of mice injected with [68Ga]Ga-FR and [68Ga]Ga-FRH confirmed findings from ex vivo biodistribution studies. In a mouse model of S. aureus myositis, both radiolabeled siderophores showed radiotracer accumulation at the site of infection. CONCLUSIONS: The 68Ga-complexes of stereoisomers ferrirubin and ferrirhodin revealed different pharmacokinetic profiles. In vitro uptake was not affected by isomerism. Both compounds had uptake with the same bacterial culture with similar efficacy. PET/CT imaging showed that the [68Ga]Ga-complexes accumulate at the site of S. aureus infection, highlighting the potential of [68Ga]Ga-FR as a promising tool for infection imaging. In contrast, retention of the radioactivity in the blood was observed for [68Ga]Ga-FRH. In conclusion, the stereoisomerism of potential radiotracers should be considered, as even minor structural differences can influence their pharmacokinetics and, consequently, the results of PET imaging.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Neuzilova, Barbora $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 779 00, Olomouc, Czech Republic
- 700 1_
- $a Dvorakova Bendova, Katerina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 779 00, Olomouc, Czech Republic
- 700 1_
- $a Novy, Zbynek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 779 00, Olomouc, Czech Republic $u Czech Advanced Technology and Research Institute, Palacky University, Krizkovskeho 511/8, 779 00, Olomouc, Czech Republic
- 700 1_
- $a Popper, Miroslav $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 779 00, Olomouc, Czech Republic
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 779 00, Olomouc, Czech Republic $u Czech Advanced Technology and Research Institute, Palacky University, Krizkovskeho 511/8, 779 00, Olomouc, Czech Republic $u University Hospital Olomouc, I.P. Pavlova 6, 779 00, Olomouc, Czech Republic
- 700 1_
- $a Petrik, Milos $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 779 00, Olomouc, Czech Republic. milos.petrik@upol.cz $u Czech Advanced Technology and Research Institute, Palacky University, Krizkovskeho 511/8, 779 00, Olomouc, Czech Republic. milos.petrik@upol.cz $1 https://orcid.org/0000000313345916
- 773 0_
- $w MED00214678 $t EJNMMI radiopharmacy and chemistry $x 2365-421X $g Roč. 9, č. 1 (2024), s. 20
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38436776 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130940 $b ABA008
- 999 __
- $a ok $b bmc $g 2075981 $s 1215421
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 9 $c 1 $d 20 $e 20240304 $i 2365-421X $m EJNMMI radiopharmacy and chemistry $n EJNMMI Radiopharm Chem $x MED00214678
- GRA __
- $a LX22NPO5103 $p Next generation (EU)
- GRA __
- $a Project ENOCH No. CZ.02.1.01/0.0/0.0/16_019/0000868 $p the European Regional Development Fund
- GRA __
- $a EATRIS-CZ LM2023053 $p the Czech Ministry of Education, Youth and Sports through project EATRIS
- LZP __
- $a Pubmed-20240405